Medical device manufacturer C.R. Bard may have known about its Recovery inferior vena cava (IVC) blood filter’s risks for complications before receiving permission to market it, according to an NBC News investigation.
Bard might have also forged a signature on its application for FDA clearance, and a private study sponsored by Bard indicated the device was riskier than similar devices long before the manufacturer removed it from the market.
IVC filters are inserted into a person’s vein to prevent blood clots from reaching the heart. The Recovery filter is associated with 27 deaths and about 300 other adverse events, according to NBC.
